Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 54Breast 8Thoracic 7Gynecologic 4Genitourinary 4Plasma cell 3CNS 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2Dermatologic 2Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Gliosarcoma 43Glioblastoma 43Brain Neoplasms 29Glioma 23Sarcoma 20Astrocytoma 13Oligodendroglioma 10Central Nervous System Neoplasms 8Colorectal Neoplasms 7Neoplasm Metastasis 6Recurrence 5Stomach Neoplasms 4Neoplasms 4Hemangiosarcoma 4Carcinoma, Hepatocellular 4Sarcoma, Kaposi 3Ovarian Neoplasms 3Osteosarcoma 3Gastrointestinal Stromal Tumors 3Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leiomyosarcoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Diffuse Intrinsic Pontine Glioma 2

Interventions

Gemcitabine 9pembrolizumab 7Irinotecan 5Docetaxel 4Cisplatin 4Carboplatin 4Capecitabine 4Albumin-Bound Paclitaxel 4Paclitaxel 3Oxaliplatin 3Leucovorin 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3pazopanib 2palbociclib 2liposomal doxorubicin 2entrectinib 2alectinib 2Vinorelbine 2Trastuzumab 2Taxes 2Radiosurgery 2Oncolytic Virotherapy 2Observation 2Ipilimumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Bevacizumab × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡